EUnetHTA 2020 Assembly – Welcome Guide now available
The annual EUnetHTA Assembly aims to provide an overview into the year’s activity, while stimulating discussion on HTA-related topics and looking to the network’s next steps and future developments. Due to current events, we will be holding the 1st April Assembly online with network members, while this year’s Forum is postponed till a later date. […]
EUnetHTA Response to COVID-19
We all are faced with an unprecedented situation, a reminder of how fragile we as individuals are, how fragile our societies remain. EUnetHTA is a network of specialists, dedicated in their own jurisdictions to excellence and the support of their individual health care systems. EUnetHTA derives its strength from its diversity, from the ability to […]
PTJA09 – Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national […]
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment […]
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) […]
EUnetHTA Magazine – Winter 2020 – Now Available
We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.
Open Call for Patient Group Input – Collaborative Assessment of (bariatric) surgical methods for treatment of morbid obesity
EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity To find out about participation, please read more here. Input submissions will be received through EOB, 20th March, 2020 EUnetHTA deems patient input very important in the production of Collaborative Assessment reports. We recognise that patients and those who support them […]
EUnetHTA releases the second version of its methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”
The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs on clinical effectiveness. In particular, the requirements presented in this methodological guideline aim to provide orientation for systematic searches on clinical effectiveness conducted within the framework of EUnetHTA. About this […]
OTCA24 – Final Project Plan and related documentation now available.
EUnetHTA is pleased to announce that the final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA24 “The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in pulse wave velocity algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular risk” are now […]
PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available
The final project plan of the relative effectiveness of ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ is now available for access. The final assessment report will be published on 12th March, 2020. Below is the documentation provided by the Joint Assessment authoring team. PTJA09 Final Project Plan
